Induction of acute lymphocytic leukemia differentiation by maintenance therapy

Maintenance therapy for B-chronic lymphocytic leukemia.

Although modern treatment options for B-chronic lymphocytic leukemia (CLL) produce high response rates, virtually all patients relapse, presumably due to the persistence of minimal residual disease (MRD). Novel approaches that maintain response and therefore delay growth of MRD may ultimately improve survival outcomes. In CLL, any type of continued therapy must be not only well tolerated but al...

The role of microRNA in acute/chronic, myeloid/lymphocytic leukemia

MicroRNAs are small, non-coding sequences that regulate gene expression by inducing degradation or translational inhibition of target mRNAs. These molecules control many intracellular physiological and pathological processes.Abnormal expression of these moleculs has been described in different cancers including hematopoietic cancers. According to the type of cancer and the stage, miRNA’s expres...

Metronomic Effect as A New Hypothesis in Maintenance Therapy of Acute Lymphoblastic Leukemia

Remission maintenance in acute lymphocytic leukemia with hydroxyurea.

After complete remission had been induced by prednisone and vincristine in children with acute leukemia, hydroxyurea was used in an effort to maintain remission. No significant prolonga tion of remission occurred despite the appearance of toxicity in over 50% of the high dosage group. An equally significant ob servation was that the duration of remission produced by predni sone and vincristine ...

acute myeloid leukemia (aml): the role of maintenance chemo¬therapy

maintenance treatment for patients with acute myeloid leukemia (aml) in remission has recently been controversially discussed and even abandoned by several groups. an analysis of 16 published multicenter trials, however, revealed the highest probabilities of relapse free survival (rfs) in the range of 35-42 % at 4-5 years only in patients assigned to maintenance treatment when adult age and int...